GlassScriptPhysician profile
Braden George Thomas
NPI 1215515473
$4,520.86
in general payments reported to CMS, 2019-2025
22 companies · $1,623 in 2025
The $1,623 reported for 2025 was more than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,898 · 2025: $1,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,775 · Travel and Lodging: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,775.05 |
| Travel and Lodging | $745.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,936.42 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Madrigal Pharmaceuticals | $1,087.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $336.17 | 2024-2025 | Epclusa, Livdelzi |
| Mallinckrodt Hospital Products INC. | $234.57 | 2024-2025 | Terlivaz |
| Abbvie INC. | $189.69 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.46 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Intercept Pharmaceuticals, INC. | $138.34 | 2024-2025 | |
| Genzyme Corporation | $52.32 | 2024-2025 | |
| Janssen Biotech, INC. | $48.76 | 2024-2025 | Stelara, Tremfya |
| Phathom Pharmaceuticals, INC. | $48.24 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $45.31 | 2025 | Iqirvo |
| Digestive Care, INC. | $43.93 | 2024 | Pertzye |
| Alnylam Pharmaceuticals INC. | $33.09 | 2024 | Givlaari |
| Eisai INC. | $30.42 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $22.68 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.84 | 2025 | Xifaxan |
| Novo Nordisk INC | $20.78 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $20.33 | 2025 | Dupixent |
| Lilly USA, LLC | $19.13 | 2024 | Omvoh |
| Aimmune Therapeutics, INC. | $18.29 | 2024 | |
| Mirum Pharmaceuticals, INC. | $16.83 | 2025 | Livmarli, Chenodal, Cholbam |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Braden Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.